Welcome to our dedicated page for Kailera Therapeutics news (Ticker: KLRA), a resource for investors and traders seeking the latest updates and insights on Kailera Therapeutics stock.
Kailera Therapeutics reports company developments tied to its transition into the public markets and its clinical-stage obesity therapeutics business. News items cover the pricing and closing of its initial public offering, the listing of KLRA common stock on the Nasdaq Global Select Market, and equity financing associated with its development-stage operations.
Company updates also frame Kailera as an advanced clinical-stage biotechnology issuer focused on obesity care, with public communications centered on capital formation, listing status, and product-candidate development in GLP-1 based obesity therapeutics.
Kailera Therapeutics (Nasdaq: KLRA) reported second quarter 2026 results and detailed progress across its GLP‑1–based obesity pipeline. The global Phase 3 KaiNETIC program of ribupatide injection in obesity remains on track with three trials enrolling over 4,700 participants and data anticipated in 2028, while a U.S. Phase 2b high‑dose obesity trial is fully enrolled with data expected in mid‑2027. An IND for ribupatide oral is active with the U.S. FDA, supporting planned global Phase 3 obesity trials in the first half of 2027. Kailera is also running a global Phase 2 obesity trial of oral GLP‑1 agonist KAI‑7535 and preparing a Phase 1 trial for tri‑agonist KAI‑4729 in 2026. As of June 30, 2026, cash, cash equivalents and marketable securities totaled $1,171.8 million, which Kailera expects will fund operations into mid‑2028, alongside higher R&D spending of $101.1 million and a quarterly net loss of $111.3 million.
Kailera Therapeutics (Nasdaq: KLRA) appointed veteran technical operations leader Nur Nicholson as Chief Technology Officer, effective August 31, 2026. Nicholson will oversee manufacturing and supply chain strategy as Kailera advances its late-stage obesity pipeline, including global Phase 3 trials of once-weekly injectable ribupatide and preparations for a Phase 3 oral program.
Kailera highlights four clinical-stage GLP-1–based candidates: ribupatide injection (KAI-9531), a once-daily oral ribupatide formulation in development, KAI-7535 (once-daily oral GLP-1 agonist), and KAI-4729 (once-weekly injectable GLP-1/GIP/glucagon tri-agonist).
Kailera Therapeutics (KLRA) reported positive topline data from two Hengrui Pharma Phase 3 trials of oral GLP-1 agonist HRS-7535/KAI-7535 in China.
In obesity/overweight, mean weight loss reached up to 10.9% at Week 44 and 11.1% at Week 50. In type 2 diabetes, HbA1c fell by 1.50%–1.68% across doses, with liver safety findings consistent with prior data and no observed liver safety signals. Kailera is running a global Phase 2 obesity trial, started April 2026, with data expected in 2027.
Kailera Therapeutics (KLRA), a clinical-stage obesity-focused biotech, appointed Kathleen Tregoning as Chief Corporate Affairs Officer. The hire supports advancement of its late-stage obesity trials and engagement with stakeholders in a rapidly evolving treatment landscape.
Tregoning brings 20+ years in global corporate affairs, with senior roles at Cerevel Therapeutics, Sanofi, and Biogen, and board positions at Compass Pathways (CMPS) and Spero Therapeutics (SPRO).
Hengrui Pharma and Kailera Therapeutics (NASDAQ:KLRA) presented new clinical data for ribupatide, a GLP-1/GIP dual agonist for obesity, at ADA 2026.
Phase 2 oral data in China showed up to 12.1% mean weight loss at 26 weeks and up to 38.6% achieving ≥15% weight loss, with mainly mild gastrointestinal events and no discontinuations for GI issues. A Phase 1 single-dose injection study outside China reported similar exposure and tolerability in Asian and non-Asian participants and mean weight loss of 1.4–5.5% vs 0.4% with placebo at Day 29.
Kailera Therapeutics (Nasdaq: KLRA), a clinical-stage biotech focused on obesity care, will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, at 10:30 a.m. EDT. A live webcast and 90-day replay will be available on the company’s investor website.
Kailera (Nasdaq: KLRA) reported Q1 2026 results and obesity pipeline updates. As of March 31, 2026, cash, equivalents and marketable securities were $581.9M, and, with $718.8M IPO gross proceeds, are expected to fund operations into mid‑2028. Q1 net loss was $78.9M.
The company initiated five late-stage global obesity trials, including the Phase 3 KaiNETIC program for ribupatide injection, and reported topline data: ribupatide oral showed up to 12.1% mean weight loss, KAI‑4729 up to 16.0% weight loss, and KAI‑7535 achieved HbA1c reductions up to 1.68%.
Kailera Therapeutics (NASDAQ:KLRA) and Hengrui Pharma will present new clinical data on ribupatide at the American Diabetes Association 86th Scientific Sessions, June 5–8, 2026, in New Orleans.
Posters cover Phase 2 oral ribupatide in obesity and a Phase 1 single-ascending dose study of injectable KAI-9531.
Hengrui Pharma (KLRA) reported Q1 2026 revenue of RMB 8.14 billion, up 12.98% YoY, and net profit attributable to shareholders of RMB 2.28 billion, up 21.78% YoY. Innovative drugs generated RMB 4.53 billion, up 25.75% YoY and 61.69% of pharmaceutical sales.
R&D spending was RMB 2.22 billion (~27.32% of revenue). The company recognized RMB 787 million in out-licensing revenue and recorded pipeline progress: 26 clinical trial approvals and 8 NDAs accepted in China. Kailera Therapeutics (NASDAQ: KLRA) completed a Nasdaq listing as a NewCo for GLP-1 assets.
Kailera (Nasdaq: KLRA) closed its initial public offering on April 20, 2026, selling 44,921,875 common shares at $16.00 per share, including full exercise of the underwriters' option for 5,859,375 additional shares.
The aggregate gross proceeds were $718.8 million before underwriting discounts, commissions and offering expenses; Kailera's common stock is listed on the Nasdaq Global Select Market under the ticker KLRA.